Clinical relevance and prognostic role of PDL-1 expression in cervical cancer patients - Summary - MDSpire

Clinical relevance and prognostic role of PDL-1 expression in cervical cancer patients

  • By

  • Antonio Arnò

  • Angelina Pernazza

  • Martina Leopizzi

  • Elena Benedettucci

  • Bruna Cerbelli

  • Lucia Manganaro

  • Giacomo Barchiesi

  • Federica Tomao

  • Giorgia Perniola

  • Violante Di Donato

  • Gabriella Gentile

  • Sofia Mancini

  • Francesca De Felice

  • Ludovico Muzii

  • Carlo Della Rocca

  • Innocenza Palaia

  • May 9, 2026

Share

Objective:

To explore the correlations between clinicopathological factors and PD-L1 expression in tumor and inflammatory cells in cervical cancer patients, emphasizing the significance of PD-L1 as a predictive biomarker for response to neoadjuvant chemotherapy (NACT).

Key Findings:
  • 76% of patients were classified as PD-L1 positive, indicating a significant prevalence.
  • PD-L1 expression was predominantly in immune cells (58%) compared to tumor cells (42%), suggesting a potential role in immune evasion.
  • Higher average CPS values were observed in patients with PD-L1 expression on neoplastic cells, which may correlate with better treatment outcomes.
Interpretation:

PD-L1 expression is prevalent in cervical cancer and may serve as a predictive biomarker for response to immunotherapy and NACT, potentially influencing treatment strategies.

Limitations:
  • Small sample size of 59 patients may limit generalizability.
  • Retrospective nature may introduce bias, and potential confounding factors should be acknowledged.
Conclusion:

PD-L1 expression correlates with clinicopathological features and may predict treatment response, highlighting its potential role in guiding immunotherapy strategies in cervical cancer and suggesting avenues for future research.

Original Source(s)

Clinical relevance and prognostic role of PDL-1 expression in cervical cancer patients

  • by Antonio Arnò, Angelina Pernazza, Martina Leopizzi, Elena Benedettucci, Bruna Cerbelli, Lucia Manganaro, Giacomo Barchiesi, Federica Tomao, Giorgia Perniola, Violante Di Donato, Gabriella Gentile, Sofia Mancini, Francesca De Felice, Ludovico Muzii, Carlo Della Rocca, Innocenza Palaia

  • May 9, 2026

Related Content

UCI Health is at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Join UCI Health at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2 in Chicago, as we showcase how Orange County’s only academic health system is advancing the future of cancer care.

  • by

  • May 8, 2026

  • 5 min
Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book

ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book.    

  • by ASCO

  • May 8, 2026

  • 2 min